ACAD News and Press, ACADIA Pharmaceuticals Inc. From 01/13/26

- 2028 projected combined net sales of approximately $1.7 billion including ~$1 billion for NUPLAZID ® and ~$700 million for DAYBUE ® - Top-line results from the Phase 2 RADIANT study of remlifanserin (formerly ACP-204) in Alzheimer’s disease psychosis anticip...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m....

2025-12-17 13:36:48 ET More on markets Apollo highlights stagflation concerns as the Fed balances inflation and jobs risks for 2026 Energy is second worst-performing sector YTD, but some stocks buck the trend, led by Valero S&P 500 tech sector soars 21% YTD, with...

2025-12-16 09:19:08 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/14/2025. The 13F portfolio value in...

2025-12-15 09:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ACAD on December 15, 2025 02:13PM ET. The previous analyst recommendation was Buy. ACAD was trading at $27.22 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

-- DAYBUE STIX provides Rett syndrome patients and caregivers with new flexibility and choice in their treatment with DAYBUE -- DAYBUE and DAYBUE STIX are the only FDA-approved treatments for Rett syndrome, a rare neurodevelopmental disorder Acadia Pharmaceuticals Inc. (Nasdaq...

2025-12-04 18:26:44 ET Introduction My last write-up on Acadia Pharmaceuticals Inc. ( ACAD ) was in March 2024. I was Buy on its stock, and ACAD has mirrored the index gains during this time.... Read the full article on Seeking Alpha For further details see: ...

2025-12-04 12:06:27 ET Ashwani Verma from UBS issued a price target of $35.00 for ACAD on 2025-12-04 14:52:00. The adjusted price target was set to $35.00. At the time of the announcement, ACAD was trading at $26.219. The overall price target consensus is at $29.75 with ...

2025-12-02 13:23:24 ET ACADIA Pharmaceuticals Inc. (ACAD) Citi Annual Global Healthcare Conference 2025 December 2, 2025 9:45 AM EST... Read the full article on Seeking Alpha For further details see: ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcar...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadia’s fireside chat will be accessible on the company&#...